Revolution Medicines, Inc. Revolution Medicines, Inc.

Revolution Medicines, Inc.

RVMD

Kedudukan dalam Saham #578
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Harga Saham
$196.16
Modal Pasaran
$42.04B
Perubahan (1 hari)
7.69%
Perubahan (1 tahun)
263.19%
Negara
US
Perdagangan Revolution Medicines, Inc. (RVMD)

Kategori

Healthcare
Bilangan saham terbitan bagi Revolution Medicines, Inc. (RVMD)
Bilangan saham terbitan setakat June 2026: 210.89M
Menurut laporan kewangan terkini dan harga saham Revolution Medicines, Inc., bilangan saham terbitan semasa ialah 210.89M. Pada akhir December 2023, syarikat mempunyai 113.15M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Revolution Medicines, Inc. (RVMD) dari 2017 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
2026 (TTM) 210.89M 25.73%
2024 167.74M 48.24%
2023 113.15M 40.34%
2022 80.63M 10.74%
2021 72.81M 9.32%
2020 66.60M 82.60%
2019 36.47M 0.00%
2018 36.47M 0.00%
2017 36.47M 0.00%
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 20.39%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 87.77%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 127.09%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -70.51%
NL